2. Apoptosis
  3. Survivin Caspase Apoptosis
  4. Anticancer agent 324

Anticancer agent 324 is a Survivin inhibitor. Anticancer agent 324 competitively binds to Survivin’s linker region and triggers proteasomal IAP degradation. Anticancer agent 324 blocks Borealin binding and chromosomal passenger complex formation, and inhibits Survivin-CRM1 nuclear-cytoplasmic transport. Anticancer agent 324 activates extrinsic (caspase-8) and intrinsic (caspase-9) apoptotic pathways, activates executioner caspases-3 and caspases-7, and arrests cell cycle. Anticancer agent 324 can be used for the research of breast cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Anticancer agent 324

Anticancer agent 324 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 324 Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 324 is a Survivin inhibitor. Anticancer agent 324 competitively binds to Survivin’s linker region and triggers proteasomal IAP degradation. Anticancer agent 324 blocks Borealin binding and chromosomal passenger complex formation, and inhibits Survivin-CRM1 nuclear-cytoplasmic transport. Anticancer agent 324 activates extrinsic (caspase-8) and intrinsic (caspase-9) apoptotic pathways, activates executioner caspases-3 and caspases-7, and arrests cell cycle. Anticancer agent 324 can be used for the research of breast cancer[1].

IC50 & Target[1]

Caspase-3

 

Caspase-7

 

Caspase-8

 

Caspase-9

 

In Vitro

Anticancer agent 324 (Compound P3) binds with higher affinity to the linker region of Survivin than cIAP1, NAIP, and XIAP, enabling it to competitively disrupt Survivin's protective interactions with these IAP family members[1].
Anticancer agent 324 (5-50 μM; 24-48 h) reduces MCF-7 human breast cancer cell viability in a time-dependent manner[1].
Anticancer agent 324 (15-45 μM; 24-48 h) induces caspase-3 and -7 activity in MCF-7 human breast cancer cells in vitro in a time-dependent manner[1].
Anticancer agent 324 (25 μM; 48 h) significantly activates both caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway) in MCF-7 human breast cancer cells[1].
Anticancer agent 324 (25 μM; 48 h) significantly increases apoptosis and mitotic catastrophe in MCF-7 human breast cancer cells after 48 h incubation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 324 Related Antibodies

Cell Viability Assay[1]

Cell Line: MCF-7 human breast cancer cells
Concentration: 5 μM; 10 μM; 15 μM; 20 μM; 25 μM; 30 μM; 35 μM; 40 μM; 45 μM; 50 μM
Incubation Time: 24 h; 48 h
Result: Reduced MCF-7 cell viability in a time-dependent manner.
Reached an IC50 of 40 μM at 24 h and 25 μM at 48 h.
Showed significant reductions in viability at all tested concentrations relative to control at 48 h, with effect sizes (Cohen's d) ranging from 6.20 to 19.52.

Apoptosis Analysis[1]

Cell Line: MCF-7 human breast cancer cells
Concentration: 15 μM; 25 μM; 35 μM; 45 μM
Incubation Time: 24 h; 48 h
Result: Increased total apoptosis to 82.78% at 25 μM, with significant increases in early apoptosis (18.7%, p = 0.0044, Cohen's d = -4.73) and late apoptosis (64.1%, p = 2.86e-05, Cohen's d = -17.4), and minimal non-significant necrosis (1.36%, p = 0.0868).
Increased total apoptosis to 23.23% at 45 μM, with significant increases only in late apoptosis (19.2%, p = 0.001, Cohen's d = 5.53) and necrosis (13.1%, p = 0.0043, Cohen's d = 5.86), while early apoptosis did not change significantly (p = 0.462).

Immunofluorescence[1]

Cell Line: MCF-7 human breast cancer cells
Concentration: 25 μM
Incubation Time: 48 h
Result: Significantly increased the proportion of non-viable cells (red fluorescence from PI) relative to control (p = 0.00011), confirming induction of apoptosis and mitotic catastrophe.
Molecular Weight

1912.18

Formula

C85H130N28O21S
Sequence

Arg-Arg-Arg-Leu-Arg-Glu-Met-Asn-Trp-Val-Asp-Tyr-Phe-Ala
Sequence Shortening

RRRLREMNWVDYFA
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 324 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 324Anticancer agent324Anticancer agent-324SurvivinCaspaseApoptosisBorealincaspase-3caspase-8caspase-7caspase-9MCF-7 human breast cancer cellCRM1IAP familychromosomal passenger complexInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 324
Cat. No.:
HY-P11828
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.